Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)

Market Cap	34.97B
Revenue (ttm)	1.24B
Net Income (ttm)	716.42M
Shares Out	616.79M
EPS (ttm)	1.16
PE Ratio	48.87
Forward PE	114.53
Dividend	0.12 (0.26%)
Ex-Dividend Date	n/a

Volume	17,703,207
Average Volume	4,746,207
Open	56.70
Previous Close	56.69
Day's Range	50.81 - 56.76
52-Week Range	15.22 - 56.69
Beta	0.41
RSI	90.91
Earnings Date	Apr 25, 2025

About SHA:688336

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of antibody drugs in China. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an initututab for injection; and Xenipax, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation, as well as used in conjunction w...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 995
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688336

Financial Performance

In 2024, SHA:688336's revenue was 1.19 billion, an increase of 17.70% compared to the previous year's 1.01 billion. Earnings were 704.58 million, an increase of 139.15%.